Administration of Aripiprazol

Introduction to Aripiprazol

• Aripiprazol is an atypical antipsychotic considered of "third generation" due to its activity as a partial agonist of dopamine D2 receptors, which distinguishes it from other antipsychotics 1

Pharmacokinetics and Metabolism

• The American Academy of Child and Adolescent Psychiatry recommends avoiding the concomitant use of aripiprazol with MAO inhibitors due to the risk of hypertensive crises 2
• Aripiprazol is metabolized in the liver by cytochrome P450, and its use should be avoided with potent inducers of this pathway (rifampicin, phenobarbital, carbamazepine, phenytoin) 3

Administration and Monitoring

• The administration of aripiprazol in the morning is recommended for most patients to optimize its metabolic safety profile and minimize adverse effects on the lipid profile 1
• Patients with a history of depression should be carefully monitored, as aripiprazol may be associated with the onset or worsening of depressive symptoms 3

Special Considerations

• The use of aripiprazol should be carefully evaluated in patients with pre-existing cardiovascular risk factors, and regular monitoring of the lipid profile is recommended 3